Due to COVID-19, we anticipate to reschedule the upcoming 2nd Drug Delivery Conference. Once we have further information, this will be updated and displayed on our website.

This conference focuses on the design parameters, synthesis and clinical validation of new drug delivery vehicles, and is designed to bridge the gap between basic science and unmet clinical needs with a particular focus on gene editing therapeutics, RNA therapeutics, sustained release technologies and immuno-engineering. Several new polymers, linkers, proteins, and nanoparticles for drug delivery will be presented, as well as recent clinical trial data generated from drug delivery companies that are pioneering the development of new experimental therapeutics. The field is rapidly evolving and it is having a significant clinical impact but there are still a number of challenges associated with accelerating the pace in transitioning into the clinic. Recent advances in chemistry, genetics and biochemistry have majorly impacted drug delivery based therapeutics and this conference aims to make these new developments accessible to a broad audience.

Key Sessions

•    Therapeutic gene editing
      - Fundamentals of gene editing and overview of gene editing modalities (protein, gene, mRNA, viral, etc.)
      - New gene editing modalities
      - Approaches to delivery of therapeutic gene editing modalities – in vivo, ex vivo
•    Extrahepatic delivery of nucleic acids
•    Characterization of therapeutic nanoparticles and control strategies for manufacturing
      - Molecular characterization
      - Physchem characterization
      - Toxicological characterization
      - New methods
      - Case studies from industry
•    New linkers for triggered or controlled release
•    New long acting technologies
•    Tumor targeting with nanoparticles, recent progress and challenges

Confirmed Keynote Speakers

Maria J. Alonso (University of Santiago de Compostela)
Patrick Couvreur (Université Paris-Saclay)
NANOMEDICINES: A NEW WAY FOR DRUG DELIVERY
Darrell Irvine (MIT/ Koch Institute for Integrative Cancer Research)
DESIGNING DELIVERY SYSTEMS TO EFFICIENTLY ACCESS TUMORS AND LYMPHOID ORGANS FOR CANCER IMMUNOTHERAPY
Marino Zerial (MPI-CBG)
METHODS TO STUDY ENDOCYTOSIS AND IMPROVE THE DELIVERY OF OLIGONUCLEOTIDE-BASED DRUGS

Confirmed Invited Speakers

Eric Appel (Stanford University)
Ana Cadete (Moderna)
Ashutosh Chilkoti (Duke University)
MOLECULAR DESIGN OF GENETICALLY ENGINEERED NANOPARTICLES FOR DRUG DELIVERY
Kenneth Dawson (Univeristy College Dublin)
Elizabeth Gillies (University of Western Ontario)
DEGRADABLE AND STIMULI-RESPONSIVE POLYMER PLATFORMS FOR DRUG DELIVERY
Young Jik Kwon (University of California Irvine)
MULTI-MODAL GENE- AND CHEMOTHERAPY FOR CANCER: EFFICIENT, SAFE, AND UNIVERSALLY-APPLICABLE
Twan Lammers (RWTH Aachen University)
SMART STRATEGIES TO IMPROVE CANCER PERFORMANCE AND TRANSLATION
Kunwoo Lee (GenEdit)
DELIVERY OF MRNA AND CRISPR RIBONUCLEOPROTEIN USING POLYMER NANOPARTICLE
Mano Manoharan (Alnylam Pharmaceuticals)
LIVING IN THE WORLD OF RNAi THERAPEUTICS
David Owen (Starpharma)
Rafaella Rossin (Tagworks Pharmaceuticals)
CLICK-TO-RELEASE STRATEGIES FOR ADCs
Gaurav Sahay (Oregon Health & Science University)
Ernst Wagner (LMU)

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the earlybird rate and bring a student for only €820. Both registration packages include; accommodation for the 20, 21, 22 July 2020 (on a shared basis for students) and a food and beverage package for the conference period. Once registered, please contact Chloe Trundle to obtain a special registration link for your student. 

Target Audience

This conference will appeal to students, postdocs, professors and all those working in the biotech industry.

Although the programme has not yet been released, we are able to confirm that the conference should begin no earlier than 14:00 with opening comments on 20th July 2020. The conference will conclude no later than 12:30 on 23rd July 2020.